City Therapeutics Closes $230M IPO as Biotech Listings Reopen
City Therapeutics has completed an upsized Nasdaq debut, raising $230 million in gross proceeds for its biotechnology pipeline.
What happened
City Therapeutics has closed an upsized initial public offering on Nasdaq, generating $230 million in gross proceeds. The larger-than-planned transaction gives the biotechnology company fresh capital to advance its development pipeline.
Why it matters
The deal is a notable test of investor appetite for clinical-stage biotechnology companies after an uneven period for new listings. An upsized offering signals that specialist investors are willing to support differentiated science when the clinical and commercial case is compelling.
The bigger picture
Successful biotech flotations can create a path for other venture-backed drug developers waiting for public markets to reopen. The next test will be whether new issuers can sustain performance after listing and convert public capital into meaningful clinical progress.